ArticleRheumatology (Oxford, England)2026
The Michael Mason prize: development and feasibility testing of a complex intervention to improve adherence to fracture prevention medicine.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectivesOnly 12% of people recommended fracture prevention medicines remain on treatment 1 year post fracture. The 'improving uptake of Fracture Prevention treatments' (iFraP) intervention aims to improve shared decision-making (SDM) about, and uptake of, osteoporosis medicines in Fracture Liaison Services (FLS). This paper details development and feasibility.
methodsIntervention development was underpinned by (i) theories of SDM, medicines adherence and behaviour change; (ii) integrated findings from seven development studies; and (iii) extensive patient and clinician contribution, identifying key 'needs' to address and the intervention's content, functionality and scope. Feasibility testing was conducted at one English FLS. Intervention consultations were observed and audio recorded. Interviews completed with FLS clinicians and patients explored perceived acceptability and feasibility.
resultsIntervention development identified patient and clinician unmet needs for personalized and evidence-based information about osteoporosis, its consequences, and its treatment within and after FLS consultations, to facilitate clinical and SDM about medicines. The prototype intervention (osteoporosis decision support tool, clinician skills training and information resources) was designed to meet identified needs and overcome barriers to use. Clinicians delivered the prototype iFraP intervention in 10 consultations with consenting patients. Findings demonstrated that the intervention was acceptable and feasible to deliver, with potential to improve patient outcomes. The intervention was refined to support implementation.
conclusionThe multi-facilitated approach to intervention development and testing ensured that the iFraP intervention appears acceptable and feasible for use in UK FLS to support SDM about osteoporosis medicines. The iFraP trial will evaluate implementation, and cost and clinical effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.